aspirin has been researched along with Critical Illness in 40 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Critical Illness: A disease or state in which death is possible or imminent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to evaluate the risk of major bleeding in non-surgical critically ill patients who received aspirin in conjunction with therapeutic anticoagulation (concomitant therapy) compared to those who received therapeutic anticoagulation alone." | 7.96 | Risk of major bleeding associated with aspirin use in non-surgical critically ill patients receiving therapeutic anticoagulation. ( Evans, K; Gajic, O; Hanson, AC; Johnson, MQ; Rayes, H; Schulte, PJ; Subat, YW; Trivedi, V; Warner, MA; Weister, T, 2020) |
| "The goal of this study is to establish the prevalence of high on-treatment platelet reactivity to aspirin (HPRA) and clopidogrel (HPRC) in patients with critical limb ischemia (CLI)." | 7.88 | Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia. ( Al-Asady, N; Caro, J; Clavijo, LC; Dhillon, A; Matthews, RV; Rowe, V; Shavelle, DM; Tun, H, 2018) |
| "Of 1,149 patients, 368 (32%) developed acute respiratory distress syndrome during the first 4 ICU days and 287 (25%) patients had prehospital aspirin use." | 7.81 | Prehospital aspirin use is associated with reduced risk of acute respiratory distress syndrome in critically ill patients: a propensity-adjusted analysis. ( Bastarache, JA; Bernard, GR; Chen, W; Janz, DR; May, AK; O'Neal, HR; Ware, LB, 2015) |
| "Aspirin has been found to improve outcomes in an animal model of transfusion-related acute lung injury." | 7.78 | The effect of aspirin in transfusion-related acute lung injury in critically ill patients. ( Binnenkade, JM; Juffermans, NP; Tuinman, PR; Vlaar, AP, 2012) |
| " This large, multicenter, randomized clinical trial was designed to compare the addition of diaspirin cross-linked hemoglobin (DCLHb) with standard care in the initial resuscitation of adults experiencing severe, uncompensated, traumatic hemorrhagic shock." | 7.71 | Monitoring a clinical trial conducted under the Food and Drug Administration regulations allowing a waiver of prospective informed consent: the diaspirin cross-linked hemoglobin traumatic hemorrhagic shock efficacy trial. ( Bechhofer, R; Berry, DA; Blue, JW; Cook, T; Cryer, H; Fisher, M; Fost, N; Houghton, J; Krome, R; Lewis, RJ; Washington, GR, 2001) |
| "Aspirin was administered to all patients once a day." | 5.56 | Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action. ( Frigieri, FC; Gianesello, L; Meconi, T; Pavoni, V; Pazzi, M; Stera, C, 2020) |
| "This meta-analysis found that aspirin use was associated with a reduction in mortality in patients with COVID-19 and not with an increased risk of bleeding." | 5.22 | Does aspirin have an effect on risk of death in patients with COVID-19? A meta-analysis. ( Feng, L; Gao, J; Liu, H; Lowe, S; Ma, S; Qu, G; Su, W; Sun, C; Sun, Y; Wu, B; Xia, W; Xie, P; Zhou, Z, 2022) |
| "Continuation of aspirin therapy during ICU stay in critically ill patients with COVID-19 who were receiving it prior to ICU admission may have a mortality benefit; nevertheless, it may be associated with an increased risk of significant bleeding." | 4.12 | Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study. ( Al Enazi, H; Al Harbi, S; Al Harthi, AF; Al Sulaiman, K; Alawad, A; Alenezi, RS; Alhuthaili, O; Aljuhani, O; Almazrou, S; Alotaibi, R; Alqahtani, RA; Alshehri, A; Alsulaiman, T; Altebainawi, AF; Bin Saleh, K; Gramish, J; Hafidh, A; Hussain, S; Kensara, R; Korayem, GB; Vishwakarma, R, 2022) |
| "We aimed to evaluate the risk of major bleeding in non-surgical critically ill patients who received aspirin in conjunction with therapeutic anticoagulation (concomitant therapy) compared to those who received therapeutic anticoagulation alone." | 3.96 | Risk of major bleeding associated with aspirin use in non-surgical critically ill patients receiving therapeutic anticoagulation. ( Evans, K; Gajic, O; Hanson, AC; Johnson, MQ; Rayes, H; Schulte, PJ; Subat, YW; Trivedi, V; Warner, MA; Weister, T, 2020) |
| "The goal of this study is to establish the prevalence of high on-treatment platelet reactivity to aspirin (HPRA) and clopidogrel (HPRC) in patients with critical limb ischemia (CLI)." | 3.88 | Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia. ( Al-Asady, N; Caro, J; Clavijo, LC; Dhillon, A; Matthews, RV; Rowe, V; Shavelle, DM; Tun, H, 2018) |
| " Conservative treatment included: (a) weight-adjusted bemiparin plus six hours/day intravenous iloprost for 28 days, (b) aspirin (100 mg/day) plus cilostazol (100 mg twice/day) after discharge, and (c) strict recommendations/monitoring for smoking cessation." | 3.85 | Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia. ( Anastasiadou, C; Galyfos, G; Geropapas, G; Giannakakis, S; Kastrisios, G; Kerasidis, S; Maltezos, C; Papacharalampous, G; Papapetrou, A; Sachmpazidis, I, 2017) |
| "Aspirin may prevent organ dysfunction in critically ill patients and mitigate transfusion associated acute lung injury." | 3.83 | Impact of aspirin use on morbidity and mortality in massively transfused cardiac surgery patients: a propensity score matched cohort study. ( Galvagno, S; Gammie, JS; Mazzeffi, M; Tanaka, K, 2016) |
| "Of 1,149 patients, 368 (32%) developed acute respiratory distress syndrome during the first 4 ICU days and 287 (25%) patients had prehospital aspirin use." | 3.81 | Prehospital aspirin use is associated with reduced risk of acute respiratory distress syndrome in critically ill patients: a propensity-adjusted analysis. ( Bastarache, JA; Bernard, GR; Chen, W; Janz, DR; May, AK; O'Neal, HR; Ware, LB, 2015) |
| "This study was conducted to determine whether there is additive benefit of dual-antiplatelet therapy (DAPT) with aspirin (acetylsalicylic acid [ASA]) and clopidogrel compared with ASA monotherapy among patients with symptomatic peripheral arterial disease." | 3.81 | Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease. ( Amsterdam, EA; Anderson, DR; Armstrong, EJ; Bang, H; Freischlag, JA; Laird, JR; Singh, GD; Yeo, KK, 2015) |
| " Patients with critical limb ischemia following stent thrombosis were included if dual antiplatelet therapy consisting of 100 mg aspirin and 75 mg clopidogrel per day had been administered over three months prior to enrollment." | 3.80 | Response to dual antiplatelet therapy in patients with peripheral artery occlusive disease suffering from critical limb ischemia. ( Baecker, C; Baro, D; Meybohm, P; Mutlak, H; Schmitz-Rixen, T; Wand, S; Weber, CF; Zacharowski, K, 2014) |
| "Aspirin has been found to improve outcomes in an animal model of transfusion-related acute lung injury." | 3.78 | The effect of aspirin in transfusion-related acute lung injury in critically ill patients. ( Binnenkade, JM; Juffermans, NP; Tuinman, PR; Vlaar, AP, 2012) |
| " This large, multicenter, randomized clinical trial was designed to compare the addition of diaspirin cross-linked hemoglobin (DCLHb) with standard care in the initial resuscitation of adults experiencing severe, uncompensated, traumatic hemorrhagic shock." | 3.71 | Monitoring a clinical trial conducted under the Food and Drug Administration regulations allowing a waiver of prospective informed consent: the diaspirin cross-linked hemoglobin traumatic hemorrhagic shock efficacy trial. ( Bechhofer, R; Berry, DA; Blue, JW; Cook, T; Cryer, H; Fisher, M; Fost, N; Houghton, J; Krome, R; Lewis, RJ; Washington, GR, 2001) |
| "Aspirin therapy was not associated with a reduction in ICU mortality (adjusted OR 1." | 2.82 | Association between aspirin therapy and the outcome in critically ill patients: a nested cohort study. ( Al Harbi, SA; Al-Dorzi, HM; Arabi, YM; Sadat, M; Tamim, HM, 2016) |
| " In this study, we investigated the effects of iloprost infusion on urinary 11-dehydro-TXB₂ and 8-iso-PGF(₂α) excretion rate, as in vivo indexes of thromboxane-dependent platelet activation and lipid peroxidation, respectively, and on platelet-derived proinflammatory sCD40L and nitric oxide bioavailability in 44 patients with CLI while on chronic treatment with low-dose aspirin." | 2.76 | Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost. ( Cuccurullo, C; Davì, G; Di Iorio, P; Di Michele, D; Di Ruscio, P; Ferrante, E; Lattanzio, S; Laurora, G; Lessiani, G; Liani, R; Sgrò, G; Simeone, E; Vazzana, N, 2011) |
| "Danaparoid sodium appears to be an efficient and safe treatment in critically ill patients with HIT." | 2.69 | Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. ( Guyotat, D; Mahul, P; Mazet, E; Mismetti, P; Reynaud, J; Tardy, B; Tardy-Poncet, B, 1999) |
| "Aspirin was administered to all patients once a day." | 1.56 | Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action. ( Frigieri, FC; Gianesello, L; Meconi, T; Pavoni, V; Pazzi, M; Stera, C, 2020) |
| "Atorvastatin 80 mg was found to be independent predictor of survival, and major amputation was found to be independent predictor of mortality." | 1.39 | Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry). ( Buszman, PE; Buszman, PP; Kiesz, RS; Konkolewska, MD; Martin, JL; Radvany, MG; Szymanski, R; Wiernek, BK; Wiernek, SL, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (7.50) | 18.2507 |
| 2000's | 2 (5.00) | 29.6817 |
| 2010's | 26 (65.00) | 24.3611 |
| 2020's | 9 (22.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bradbury, CA | 1 |
| Lawler, PR | 1 |
| Stanworth, SJ | 1 |
| McVerry, BJ | 1 |
| McQuilten, Z | 1 |
| Higgins, AM | 1 |
| Mouncey, PR | 1 |
| Al-Beidh, F | 1 |
| Rowan, KM | 1 |
| Berry, LR | 1 |
| Lorenzi, E | 1 |
| Zarychanski, R | 1 |
| Arabi, YM | 2 |
| Annane, D | 1 |
| Beane, A | 1 |
| van Bentum-Puijk, W | 1 |
| Bhimani, Z | 1 |
| Bihari, S | 1 |
| Bonten, MJM | 1 |
| Brunkhorst, FM | 1 |
| Buzgau, A | 1 |
| Buxton, M | 1 |
| Carrier, M | 1 |
| Cheng, AC | 1 |
| Cove, M | 1 |
| Detry, MA | 1 |
| Estcourt, LJ | 1 |
| Fitzgerald, M | 1 |
| Girard, TD | 1 |
| Goligher, EC | 1 |
| Goossens, H | 1 |
| Haniffa, R | 1 |
| Hills, T | 1 |
| Huang, DT | 1 |
| Horvat, CM | 1 |
| Hunt, BJ | 1 |
| Ichihara, N | 1 |
| Lamontagne, F | 1 |
| Leavis, HL | 1 |
| Linstrum, KM | 1 |
| Litton, E | 1 |
| Marshall, JC | 1 |
| McAuley, DF | 1 |
| McGlothlin, A | 1 |
| McGuinness, SP | 1 |
| Middeldorp, S | 1 |
| Montgomery, SK | 1 |
| Morpeth, SC | 1 |
| Murthy, S | 1 |
| Neal, MD | 1 |
| Nichol, AD | 1 |
| Parke, RL | 1 |
| Parker, JC | 1 |
| Reyes, LF | 1 |
| Saito, H | 1 |
| Santos, MS | 1 |
| Saunders, CT | 1 |
| Serpa-Neto, A | 1 |
| Seymour, CW | 1 |
| Shankar-Hari, M | 1 |
| Singh, V | 1 |
| Tolppa, T | 1 |
| Turgeon, AF | 1 |
| Turner, AM | 1 |
| van de Veerdonk, FL | 1 |
| Green, C | 1 |
| Lewis, RJ | 2 |
| Angus, DC | 1 |
| McArthur, CJ | 1 |
| Berry, S | 1 |
| Derde, LPG | 1 |
| Webb, SA | 1 |
| Gordon, AC | 1 |
| Al Harthi, AF | 1 |
| Aljuhani, O | 1 |
| Korayem, GB | 1 |
| Altebainawi, AF | 1 |
| Alenezi, RS | 1 |
| Al Harbi, S | 1 |
| Gramish, J | 1 |
| Kensara, R | 1 |
| Hafidh, A | 1 |
| Al Enazi, H | 1 |
| Alawad, A | 1 |
| Alotaibi, R | 1 |
| Alshehri, A | 1 |
| Alhuthaili, O | 1 |
| Vishwakarma, R | 1 |
| Bin Saleh, K | 1 |
| Alsulaiman, T | 1 |
| Alqahtani, RA | 1 |
| Hussain, S | 1 |
| Almazrou, S | 1 |
| Al Sulaiman, K | 1 |
| Ma, S | 1 |
| Su, W | 1 |
| Sun, C | 1 |
| Lowe, S | 1 |
| Zhou, Z | 1 |
| Liu, H | 1 |
| Qu, G | 1 |
| Xia, W | 1 |
| Xie, P | 1 |
| Wu, B | 1 |
| Gao, J | 1 |
| Feng, L | 1 |
| Sun, Y | 1 |
| Eman, A | 1 |
| Balaban, O | 1 |
| Süner, KÖ | 1 |
| Cırdı, Y | 1 |
| Şahin, F | 1 |
| Demir, G | 1 |
| Pekşen, Ö | 1 |
| Musmul, A | 1 |
| Erdem, AF | 1 |
| Subat, YW | 1 |
| Rayes, H | 1 |
| Hanson, AC | 1 |
| Johnson, MQ | 1 |
| Schulte, PJ | 1 |
| Evans, K | 1 |
| Weister, T | 1 |
| Trivedi, V | 1 |
| Gajic, O | 1 |
| Warner, MA | 1 |
| Biagioni, RB | 1 |
| Lopes, RD | 1 |
| Agati, LB | 1 |
| Sacilotto, R | 1 |
| Wolosker, N | 1 |
| Sobreira, ML | 1 |
| de Freitas Soares, BL | 1 |
| Joviliano, EE | 1 |
| Bernardi, WH | 1 |
| Junior, VC | 1 |
| Caffaro, RA | 1 |
| Fioranelli, A | 1 |
| Van Bellen, B | 1 |
| Casella, IB | 1 |
| Fidelis, RJR | 1 |
| Flumignan, RLG | 1 |
| Comerota, AJ | 1 |
| Ramacciotti, E | 1 |
| Cioccari, L | 1 |
| Luethi, N | 1 |
| Duong, T | 1 |
| Ryan, E | 1 |
| Cutuli, SL | 1 |
| Lloyd-Donald, P | 1 |
| Eastwood, GM | 1 |
| Peck, L | 1 |
| Young, H | 1 |
| Vaara, ST | 1 |
| French, CJ | 1 |
| Orford, N | 1 |
| Dwivedi, J | 1 |
| Lankadeva, YR | 1 |
| Bailey, M | 1 |
| Reid, GE | 1 |
| Bellomo, R | 1 |
| Pavoni, V | 1 |
| Gianesello, L | 1 |
| Pazzi, M | 1 |
| Stera, C | 1 |
| Meconi, T | 1 |
| Frigieri, FC | 1 |
| Karruli, A | 1 |
| Boccia, F | 1 |
| Gagliardi, M | 1 |
| Patauner, F | 1 |
| Ursi, MP | 1 |
| Sommese, P | 1 |
| De Rosa, R | 1 |
| Murino, P | 1 |
| Ruocco, G | 1 |
| Corcione, A | 1 |
| Andini, R | 1 |
| Zampino, R | 1 |
| Durante-Mangoni, E | 1 |
| Schoergenhofer, C | 1 |
| Hobl, EL | 1 |
| Schwameis, M | 1 |
| Gelbenegger, G | 1 |
| Staudinger, T | 1 |
| Heinz, G | 1 |
| Speidl, WS | 1 |
| Zauner, C | 1 |
| Reiter, B | 1 |
| Lang, I | 1 |
| Jilma, B | 1 |
| Galyfos, G | 1 |
| Kerasidis, S | 1 |
| Kastrisios, G | 1 |
| Giannakakis, S | 1 |
| Sachmpazidis, I | 1 |
| Anastasiadou, C | 1 |
| Geropapas, G | 1 |
| Papapetrou, A | 1 |
| Papacharalampous, G | 1 |
| Maltezos, C | 1 |
| Du, F | 1 |
| Jiang, P | 1 |
| He, S | 1 |
| Song, D | 1 |
| Xu, F | 1 |
| Clavijo, LC | 1 |
| Al-Asady, N | 1 |
| Dhillon, A | 1 |
| Matthews, RV | 1 |
| Caro, J | 1 |
| Tun, H | 1 |
| Rowe, V | 1 |
| Shavelle, DM | 1 |
| Uber, AM | 1 |
| Montez-Rath, ME | 1 |
| Kwiatkowski, DM | 1 |
| Krawczeski, CD | 1 |
| Sutherland, SM | 1 |
| Gassman, AA | 1 |
| Degner, BC | 1 |
| Al-Nouri, O | 1 |
| Philippi, L | 1 |
| Hershberger, R | 1 |
| Halandras, P | 1 |
| Aulivola, B | 1 |
| Milner, R | 1 |
| Aslam, R | 1 |
| Ducrocq, N | 1 |
| Thivilier, C | 1 |
| Perez, P | 1 |
| Gerard, A | 1 |
| Kimmoun, A | 1 |
| Levy, B | 1 |
| Faustino, EV | 1 |
| Hanson, S | 1 |
| Spinella, PC | 1 |
| Tucci, M | 1 |
| O'Brien, SH | 1 |
| Nunez, AR | 1 |
| Yung, M | 1 |
| Truemper, E | 1 |
| Qin, L | 1 |
| Li, S | 1 |
| Marohn, K | 1 |
| Randolph, AG | 1 |
| Gist, KM | 1 |
| Chima, RS | 1 |
| Chen, W | 1 |
| Janz, DR | 1 |
| Bastarache, JA | 1 |
| May, AK | 1 |
| O'Neal, HR | 1 |
| Bernard, GR | 1 |
| Ware, LB | 1 |
| Wand, S | 1 |
| Baro, D | 1 |
| Baecker, C | 1 |
| Meybohm, P | 1 |
| Schmitz-Rixen, T | 1 |
| Zacharowski, K | 1 |
| Mutlak, H | 1 |
| Weber, CF | 1 |
| Palakshappa, JA | 1 |
| Christie, JD | 1 |
| Armstrong, EJ | 1 |
| Anderson, DR | 1 |
| Yeo, KK | 1 |
| Singh, GD | 1 |
| Bang, H | 1 |
| Amsterdam, EA | 1 |
| Freischlag, JA | 1 |
| Laird, JR | 1 |
| Epperly, H | 1 |
| Vaughn, FL | 1 |
| Mosholder, AD | 1 |
| Maloney, EM | 1 |
| Rubinson, L | 1 |
| Misra, DP | 1 |
| Chowdhury, AC | 1 |
| Lal, H | 1 |
| Mohindra, N | 1 |
| Agarwal, V | 1 |
| Al Harbi, SA | 1 |
| Tamim, HM | 1 |
| Al-Dorzi, HM | 1 |
| Sadat, M | 1 |
| Mazzeffi, M | 1 |
| Galvagno, S | 1 |
| Gammie, JS | 1 |
| Tanaka, K | 1 |
| Soden, PA | 1 |
| Zettervall, SL | 1 |
| Ultee, KH | 1 |
| Landon, BE | 1 |
| O'Malley, AJ | 1 |
| Goodney, PP | 1 |
| DeMartino, RR | 1 |
| Arya, S | 1 |
| Schermerhorn, ML | 1 |
| Thott, O | 1 |
| Granath, F | 1 |
| Malmstedt, J | 1 |
| Wahlgren, CM | 1 |
| Rothenberg, FG | 1 |
| Clay, MB | 1 |
| Jamali, H | 1 |
| Vandivier-Pletsch, RH | 1 |
| Hase, T | 1 |
| Sirajuddin, S | 1 |
| Maluso, P | 1 |
| Bangalore, R | 1 |
| DePalma, L | 1 |
| Sarani, B | 1 |
| Lessiani, G | 1 |
| Vazzana, N | 1 |
| Cuccurullo, C | 1 |
| Di Michele, D | 1 |
| Laurora, G | 1 |
| Sgrò, G | 1 |
| Di Ruscio, P | 1 |
| Simeone, E | 1 |
| Di Iorio, P | 1 |
| Lattanzio, S | 1 |
| Liani, R | 1 |
| Ferrante, E | 1 |
| Davì, G | 1 |
| Ramponi, F | 1 |
| Wilson, MK | 1 |
| Vedelago, J | 1 |
| Bayfield, MS | 1 |
| Tuinman, PR | 1 |
| Vlaar, AP | 1 |
| Binnenkade, JM | 1 |
| Juffermans, NP | 1 |
| Eisen, DP | 1 |
| Reid, D | 1 |
| McBryde, ES | 1 |
| Kiesz, RS | 1 |
| Wiernek, SL | 1 |
| Wiernek, BK | 1 |
| Radvany, MG | 1 |
| Buszman, PP | 1 |
| Szymanski, R | 1 |
| Konkolewska, MD | 1 |
| Martin, JL | 1 |
| Buszman, PE | 1 |
| Reah, G | 1 |
| Bodenham, AR | 1 |
| Mallick, A | 1 |
| Daily, EK | 1 |
| Przybelski, RJ | 1 |
| Tardy-Poncet, B | 1 |
| Tardy, B | 1 |
| Reynaud, J | 1 |
| Mahul, P | 1 |
| Mismetti, P | 1 |
| Mazet, E | 1 |
| Guyotat, D | 1 |
| Kobza, II | 1 |
| Freeman, BD | 1 |
| Danner, RL | 1 |
| Banks, SM | 1 |
| Natanson, C | 1 |
| Berry, DA | 1 |
| Cryer, H | 1 |
| Fost, N | 1 |
| Krome, R | 1 |
| Washington, GR | 1 |
| Houghton, J | 1 |
| Blue, JW | 1 |
| Bechhofer, R | 1 |
| Cook, T | 1 |
| Fisher, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia[NCT02735707] | Phase 3 | 10,000 participants (Anticipated) | Interventional | 2016-04-11 | Recruiting | ||
| Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb[NCT04229264] | Phase 3 | 200 participants (Anticipated) | Interventional | 2020-01-09 | Recruiting | ||
| Retrospective Single-center Cohort Study to Evaluate the Incidence of Colonization by Multidrug-resistant Organisms in Mechanically Ventilated Patients With Severe COVID-19 Admitted to a Large Intensive Care Unit in Milan, Italy[NCT05293418] | 435 participants (Actual) | Observational | 2020-10-01 | Completed | |||
| Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547] | 88 participants (Actual) | Observational | 2018-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for aspirin and Critical Illness
| Article | Year |
|---|---|
Does aspirin have an effect on risk of death in patients with COVID-19? A meta-analysis.
Topics: Aspirin; COVID-19 Drug Treatment; Critical Illness; Hemorrhage; Humans; Pandemics | 2022 |
Antiplatelet Therapy for Critically Ill Patients: A Pairwise and Bayesian Network Meta-Analysis.
Topics: Acute Lung Injury; Aspirin; Critical Illness; Hospital Mortality; Humans; Incidence; Network Meta-An | 2018 |
Gangrene in Takayasu's arteritis: a report of two cases and review of literature.
Topics: Adolescent; Adrenal Cortex Hormones; Amputation, Surgical; Anticoagulants; Aspirin; Critical Illness | 2016 |
Systematic review of β blocker, aspirin, and statin in critically ill patients: importance of severity of illness and cardiac troponin.
Topics: Adrenergic beta-Antagonists; Aspirin; Critical Illness; Humans; Hydroxymethylglutaryl-CoA Reductase | 2017 |
9 trials available for aspirin and Critical Illness
| Article | Year |
|---|---|
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Topics: Adult; Anticoagulants; Aspirin; Bayes Theorem; COVID-19; COVID-19 Drug Treatment; Critical Illness; | 2022 |
Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial.
Topics: Angioplasty; Aspirin; Clopidogrel; Critical Illness; Factor Xa Inhibitors; Humans; Ischemia; Leg; Mu | 2020 |
Cytokine and lipid metabolome effects of low-dose acetylsalicylic acid in critically ill patients with systemic inflammation: a pilot, feasibility, multicentre, randomised, placebo-controlled trial.
Topics: Aspirin; Australia; Critical Illness; Cytokines; Double-Blind Method; Feasibility Studies; Humans; I | 2020 |
Acetylsalicylic acid in critically ill patients: a cross-sectional and a randomized trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Aspirin; Critical Illness; Cross-Sectional Studies | 2017 |
Association between aspirin therapy and the outcome in critically ill patients: a nested cohort study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Comorbidi | 2016 |
Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; CD40 Ligand; Chi-Square Distribution; | 2011 |
Initial evaluation of diaspirin cross-linked hemoglobin (DCLHb) as a vasopressor in critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Creatinine; Critical Illness; Drug Monitoring; Female; Hemo | 1997 |
Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Coagulation Factors; Chondroitin Sulf | 1999 |
[The drug prevention of postoperative thromboses in patients with critical lower limb ischemia].
Topics: Anticoagulants; Aspirin; Critical Illness; Humans; Ischemia; Leg; Nadroparin; Platelet Aggregation I | 1999 |
27 other studies available for aspirin and Critical Illness
| Article | Year |
|---|---|
Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study.
Topics: Adult; Aspirin; COVID-19; Critical Illness; Hemorrhage; Humans; Intensive Care Units; Propensity Sco | 2022 |
The effect of low-dose and high-dose low-molecular-weight-heparin and aspirin thromboprophylaxis on clinical outcome and mortality in critical ill patients with COVID-19: A retrospective cohort study.
Topics: Anticoagulants; Aspirin; COVID-19; Critical Illness; Hemorrhage; Heparin, Low-Molecular-Weight; Huma | 2022 |
Risk of major bleeding associated with aspirin use in non-surgical critically ill patients receiving therapeutic anticoagulation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Critical Illness; Drug Therapy, Co | 2020 |
Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action.
Topics: Adult; Aged; Anticoagulants; Aspirin; COVID-19; Critical Illness; Female; Hemorrhage; Heparin, Low-M | 2020 |
Multidrug-Resistant Infections and Outcome of Critically Ill Patients with Coronavirus Disease 2019: A Single Center Experience.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Anti-Bacterial Agents; Aspirin; Carb | 2021 |
Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia.
Topics: Adult; Amputation, Surgical; Ankle Brachial Index; Anticoagulants; Arteritis; Aspirin; Cardiovascula | 2017 |
Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Critical Il | 2018 |
Nephrotoxin exposure and acute kidney injury in critically ill children undergoing congenital cardiac surgery.
Topics: Acute Kidney Injury; Adolescent; Aspirin; Cardiac Surgical Procedures; Child; Child, Preschool; Crit | 2018 |
Aspirin usage is associated with improved prosthetic infrainguinal bypass graft patency.
Topics: Amputation, Surgical; Aspirin; Blood Vessel Prosthesis Implantation; Comorbidity; Critical Illness; | 2014 |
Critical illness-related corticosteroid insufficiency in cardiogenic shock.
Topics: Adrenal Insufficiency; Adrenergic alpha-Agonists; Adult; Anti-Inflammatory Agents; Antihypertensive | 2013 |
A multinational study of thromboprophylaxis practice in critically ill children.
Topics: Adolescent; Anticoagulants; Aspirin; Child; Child, Preschool; Critical Care; Critical Illness; Cross | 2014 |
The landscape of thromboprophylaxis utilization in critically ill children: sparse and variable.
Topics: Anticoagulants; Aspirin; Critical Illness; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; M | 2014 |
Prehospital aspirin use is associated with reduced risk of acute respiratory distress syndrome in critically ill patients: a propensity-adjusted analysis.
Topics: Aged; Aspirin; Cohort Studies; Critical Illness; Female; Humans; Male; Middle Aged; Respiratory Dist | 2015 |
Response to dual antiplatelet therapy in patients with peripheral artery occlusive disease suffering from critical limb ischemia.
Topics: Aged; Aged, 80 and over; Area Under Curve; Aspirin; Clopidogrel; Critical Illness; Drug Resistance; | 2014 |
Prehospital aspirin use and acute respiratory distress syndrome--a case for aspirin in the drinking water?
Topics: Aspirin; Critical Illness; Female; Humans; Male; Respiratory Distress Syndrome | 2015 |
Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; California; Cardiovascular Diseases; | 2015 |
Nonsteroidal Anti-Inflammatory Drug and Aspirin Use, and Mortality among Critically Ill Pandemic H1N1 Influenza Patients: an Exploratory Analysis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Critical Illness; Female; Humans; In | 2016 |
Impact of aspirin use on morbidity and mortality in massively transfused cardiac surgery patients: a propensity score matched cohort study.
Topics: Acute Lung Injury; Aged; Aspirin; Blood Transfusion; Cardiac Surgical Procedures; Cohort Studies; Cr | 2016 |
Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization.
Topics: Aged; Aged, 80 and over; Aspirin; Chi-Square Distribution; Critical Illness; Drug Therapy, Combinati | 2016 |
Editor's Choice - Dual Antiplatelet Therapy Improves Outcome in Diabetic Patients Undergoing Endovascular Femoropopliteal Stenting for Critical Limb Ischaemia.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Clopidogrel; Constriction, Pathologic | 2017 |
Platelet dysfunction in critically ill patients.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Platelet Disorders; Critical Illness; | 2017 |
Catastrophic pulmonary and paradoxical embolism.
Topics: Angiography; Aspirin; Cardiac Surgical Procedures; Critical Illness; Echocardiography, Transesophage | 2011 |
The effect of aspirin in transfusion-related acute lung injury in critically ill patients.
Topics: Acute Lung Injury; Adult; Aged; APACHE; Aspirin; Case-Control Studies; Cohort Studies; Critical Care | 2012 |
Acetyl salicylic acid usage and mortality in critically ill patients with the systemic inflammatory response syndrome and sepsis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Critical Illness; Female; Hospital Mortality | 2012 |
Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry).
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Atherectomy; Atorvastatin; Cardiovasc | 2013 |
Safeguarding patients in clinical trials with high mortality rates.
Topics: Aspirin; Blood Substitutes; Clinical Trials as Topic; Critical Illness; Hemoglobins; Human Growth Ho | 2001 |
Monitoring a clinical trial conducted under the Food and Drug Administration regulations allowing a waiver of prospective informed consent: the diaspirin cross-linked hemoglobin traumatic hemorrhagic shock efficacy trial.
Topics: Aspirin; Critical Illness; Female; Follow-Up Studies; Hemoglobins; Humans; Informed Consent; Injury | 2001 |